Company intelligence / Profile preview

EyeYon Medical

Ownership: Private
Development stage: Commercial

Overview

EyeYon’s EndoArt® synthetic implant has received FDA Breakthrough Device Designation and has been successfully implanted in patients internationally. The company’s Hyper‑CL™ therapeutic contact lens has demonstrated efficacy as a drug delivery platform for treating recalcitrant neurotrophic keratopathy and other corneal diseases. Clinical trials are ongoing or completed for both products.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

2 assets

EndoArt

Commercial

Indications: Corneal edema, Corneal blindness

1 more asset in the full pipeline.

Request access →

Partnerships

Strategic partnerships with local Chinese healthcare ecosystem partnersCR‑CP Life Science FundGlobal Health Sciences FundTriventuresRimonciPontifaxDiamond BioFund

Beyond the preview

Go deeper on EyeYon Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeYon Medical.

Explore the full profile